Company Information

  

Address: 1010 ATLANTIC AVENUE
SUITE 102 
City: ALAMEDA 
State: CA 
Zip Code: 94501 
Telephone: 510-521-3390 

Description of Business

Primary SIC Code: 2836
(As filed with the SEC)  

BioTime is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Our clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. The foundation of our cell delivery platform is its HyStem® cell and drug delivery matrix technology. Our current clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell/drug delivery. We also have significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. ("Asterias") and OncoCyte Corporation ("OncoCyte"), which we founded and which, until recently, were our majority-owned consolidated subsidiaries.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-0.57NAN/E
03/2017-0.18NAN/E
12/2016-0.83NAN/E
09/20160.23NA16.96
06/2016-0.26NAN/E
03/2016-0.65NAN/E
12/2015-0.55NAN/E
09/2015-0.54NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity0.11Total Liab/Total Assets0.17
Net Inc/Total Assets0.24Total Liab/Inv Cap0.19
Net Inc/Inv Cap0.25Total Liab/Comm Equity0.08
Pretax Inc/Net Sales3.14Interest Coverage Ratio25.93
Net Inc/Net Sales5.67Curr Debt/Equity0.01
Cash Flow/Net Sales-7.15LTD/Equity0.02
SG&A/NetSales4.80Total Debt/Equity0.03
Asset Utilization   Liquidity  
Net Receivables Turnover4.23Quick Ratio2.90
Inventory TurnoverNACurrent Ratio2.90
Inventory Day SalesNANet Rec/Curr Assets0.05
Net Sales/Work Cap0.35Inv/Curr AssetsNA
Net Sales/PP&E1.07  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 0.38 0.39 1.08 1.50
Cost of Goods Sold 0.01 0.06 -0.02 0.06
Selling & Admin Exps 4.42 5.10 5.34 4.57
Operating Income -10.32 -11.26 -11.25 -9.55
Interest Exp 0.41 0.31 0.75 -0.09
Pretax Income -16.10 50.90 -7.74 29.01
Other Income 2.37 72.42 -0.60 -0.17
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -11.65 49.29 -5.08 31.21

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 20.87 24.73 22.72 31.35
Receivables - Total 3.07 3.01 1.16 1.72
Inventories - Total NA NA NA NA
Total Current Assets 25.53 29.26 25.65 35.15
Net Property, Plant & Equipment 5.24 4.99 5.53 4.73
Total Assets 193.35 205.22 142.57 147.57
Liabilities        
Accounts Payable 5.13 6.95 7.14 7.18
Debt in Current Liabilities 2.68 1.19 1.13 0.63
Total Current Liabilities 13.53 8.82 8.85 8.34
Long-Term Debt 1.40 2.52 2.85 2.56
Total Liabilities 17.23 17.84 24.64 28.18
Stockholder's Equity        
Minority Interest 2.06 2.33 12.58 16.85
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 334.54 334.00 317.88 313.51
Retained Earnings -158.68 -147.03 -196.32 -190.53
Treasury Stock 0.00 0.00 -2.89 -2.89
Total Stockholders' Equity 176.13 187.37 117.93 119.39
Total Liabilities and Stockholders' Equity 193.35 205.22 142.57 147.57

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -9.06 -8.10 -8.85 -8.92
Net Cash Provided by Investing Activities -5.33 -9.15 -0.41 -0.46
Net Cash Provided by Financing Activities 4.92 19.10 0.84 12.21

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20123.92-21.43-0.41
12/20134.43-43.88-0.76
12/20145.24-36.41-0.52
12/20157.04-46.99-0.55
12/20165.9233.57-0.83
Growth Rates10.90----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/1711548,05039.88




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.